Vanguard Group Inc. increased its stake in shares of Meridian Bioscience Inc. (NASDAQ:VIVO) by 1.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,684,505 shares of the company’s stock after buying an additional 70,081 shares during the period. Vanguard Group Inc. owned about 0.09% of Meridian Bioscience worth $50,846,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. FMR LLC bought a new stake in Meridian Bioscience during the fourth quarter valued at $2,515,000. Teachers Advisors LLC increased its stake in Meridian Bioscience by 2.7% in the fourth quarter. Teachers Advisors LLC now owns 69,137 shares of the company’s stock valued at $1,224,000 after buying an additional 1,828 shares in the last quarter. Bank of Montreal Can increased its stake in Meridian Bioscience by 1,690.1% in the first quarter. Bank of Montreal Can now owns 12,280 shares of the company’s stock valued at $169,000 after buying an additional 11,594 shares in the last quarter. Louisiana State Employees Retirement System increased its stake in Meridian Bioscience by 1.8% in the first quarter. Louisiana State Employees Retirement System now owns 17,200 shares of the company’s stock valued at $237,000 after buying an additional 300 shares in the last quarter. Finally, Legato Capital Management LLC increased its stake in Meridian Bioscience by 1,280.0% in the first quarter. Legato Capital Management LLC now owns 29,132 shares of the company’s stock valued at $2,111,000 after buying an additional 27,021 shares in the last quarter. 85.83% of the stock is owned by hedge funds and other institutional investors.

Meridian Bioscience Inc. (VIVO) opened at 13.60 on Thursday. The company’s 50-day moving average is $14.93 and its 200 day moving average is $14.02. The stock has a market capitalization of $573.95 million, a price-to-earnings ratio of 27.20 and a beta of 0.89. Meridian Bioscience Inc. has a one year low of $10.75 and a one year high of $19.85.

Meridian Bioscience (NASDAQ:VIVO) last issued its quarterly earnings data on Thursday, July 27th. The company reported $0.16 EPS for the quarter, hitting the consensus estimate of $0.16. Meridian Bioscience had a net margin of 10.77% and a return on equity of 16.93%. The firm had revenue of $50.14 million for the quarter, compared to analyst estimates of $49.13 million. During the same period in the prior year, the business posted $0.21 EPS. The business’s revenue for the quarter was down 1.0% compared to the same quarter last year. Equities analysts expect that Meridian Bioscience Inc. will post $0.67 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, August 17th. Stockholders of record on Monday, August 7th will be issued a $0.125 dividend. The ex-dividend date of this dividend is Thursday, August 3rd. This represents a $0.50 annualized dividend and a dividend yield of 3.68%. Meridian Bioscience’s dividend payout ratio is currently 98.04%.

COPYRIGHT VIOLATION NOTICE: “Meridian Bioscience Inc. (VIVO) Shares Bought by Vanguard Group Inc.” was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.watchlistnews.com/meridian-bioscience-inc-vivo-shares-bought-by-vanguard-group-inc/1469619.html.

Several analysts have recently weighed in on VIVO shares. Zacks Investment Research raised shares of Meridian Bioscience from a “sell” rating to a “hold” rating in a research note on Saturday, April 29th. Canaccord Genuity lifted their price target on shares of Meridian Bioscience from $13.00 to $15.00 and gave the company a “hold” rating in a research note on Wednesday, May 3rd. Finally, BidaskClub downgraded shares of Meridian Bioscience from a “buy” rating to a “hold” rating in a research note on Thursday, July 6th. Three investment analysts have rated the stock with a sell rating and four have given a hold rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $14.75.

About Meridian Bioscience

Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.

Want to see what other hedge funds are holding VIVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Meridian Bioscience Inc. (NASDAQ:VIVO).

Institutional Ownership by Quarter for Meridian Bioscience (NASDAQ:VIVO)

Receive News & Ratings for Meridian Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.